Understanding TXK: A Potential Drug Target for Cancer and Other Diseases

Target Name: TXK

NCBI ID: G7294

Content of Review Report on TXK Target / Biomarker

TXK

Understanding TXK: A Potential Drug Target for Cancer and Other Diseases

TXK (TKL), also known as 2-phenyl-1-propanethiol (2-PPT), is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth and differentiation, and has been linked to the development and progression of many diseases, including cancer. Despite its potential as a drug target, TXK has yet to be fully understood, and research into its biology and potential therapeutic applications continues to grow.

TXK was first identified in the 1990s as a regulator of cell cycle progression in cancer cells. Since then, numerous studies have demonstrated that it plays a critical role in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). TXK is also involved in the regulation of cell adhesion, migration, and the response to chemotherapy.

One of the key functions of TXK is its ability to induce cell apoptosis, which is the process by which cells automatically execute programmed cell death. This process is essential for the maintenance of tissue homeostasis and is often triggered by environmental stressors, such as exposure to chemotherapy drugs. TXK has been shown to induce apoptosis in a variety of cell types, including cancer cells, and may be a potential therapeutic target for cancer treatment.

Another important function of TXK is its role in cell adhesion and migration. TXK is involved in the regulation of cell-cell adhesion, which is the interaction between cells that results in the formation of tight junctions and adherens junctions, which are essential for maintaining tissue structure and function. TXK is also involved in the regulation of cell migration, which is the movement of cells towards new targets in the body. This function is critical for the development and progression of many diseases, including cancer.

TXK is also involved in the regulation of the cell cycle. It is a key regulator of the G1 phase of the cell cycle, which is the stage of cell growth and preparation for cell division. TXK plays a critical role in the regulation of the G1 phase by inhibiting the activity of the cyclin D1 protein, which is involved in the G1-S transition. This interaction between TXK and cyclin D1 is important for the regulation of cell cycle progression and the maintenance of tissue homeostasis.

In addition to its role in cell regulation, TXK has also been shown to have potential therapeutic applications. For example, TXK has been shown to be downregulated in the tissues of many cancer types, including breast cancer, lung cancer, and colon cancer. This suggests that targeting TXK may be a promising strategy for the treatment of these diseases. Additionally, TXK has been shown to be involved in the regulation of angiogenesis, which is the formation of new blood vessels in the body. This suggests that targeting TXK may also be a promising strategy for the treatment of diseases that are characterized by the buildup of new blood vessels, such as heart disease and diabetes.

Despite its potential as a drug target, TXK has yet to be fully understood. There is a need for further research to investigate the biology of TXK and its potential therapeutic applications. This may include studies of its structure and function, as well as its regulation by various enzymes and factors. Additionally, there is a need for further research to determine the efficacy and safety of targeting TXK as a therapeutic agent. This may include studies of its efficacy in preclinical models of cancer treatment, as well as its safety in clinical trials.

In conclusion, TXK is a protein that is expressed in various tissues throughout the body and is involved in the regulation of cell growth, apoptosis, angiogenesis, and cell cycle progression. Its potential as a drug target is an exciting area of research, and there is a need for further studies to fully understand its biology and potential therapeutic applications.

Protein Name: TXK Tyrosine Kinase

Functions: Non-receptor tyrosine kinase that plays a redundant role with ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation leads to the recruitment of TXK to the cell membrane, where it is phosphorylated at Tyr-420. Phosphorylation leads to TXK full activation. Contributes also to signaling from many receptors and participates in multiple downstream pathways, including regulation of the actin cytoskeleton. Like ITK, can phosphorylate PLCG1, leading to its localization in lipid rafts and activation, followed by subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Plays a role in the positive regulation of IFNG transcription in T-helper 1 cells as part of an IFNG promoter-binding complex with PARP1 and EEF1A1 (PubMed:11859127, PubMed:17177976). Within the complex, phosphorylates both PARP1 and EEF1A1 (PubMed:17177976). Phosphorylates also key sites in LCP2 leading to the up-regulation of Th1 preferred cytokine IL-2. Phosphorylates 'Tyr-201' of CTLA4 which leads to the association of PI-3 kinase with the CTLA4 receptor

The "TXK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TXK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets